- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly introducing Mounjaro via the NHS and facing US pricing pressure from Trump.
3 reports, 3 independent
Updated Jul 13
Gone quiet
- Reports
- 3
- Developments
- 4
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly introducing Mounjaro via the NHS and facing US pricing pressure from Trump.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Eli Lilly and Novo Nordisk are competing in the GLP-1 market, with the new development showing they are also partnering with companies like Becton, Dickinson and Company to provide specialized prefillable syringes for drug delivery.Sub-event
- Health Canada authorized the use of Eli Lilly's Mounjaro in Canada.Sub-event
Mounjaro is launching and gaining reimbursement approval across Europe.1 source
Lilly introduced Mounjaro via NHS while facing Trump pressure on US drug prices.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
Related events
Coverage
Newest first; wire copies grouped- foreignpolicyjournal.com
- yahoo.com
- BloombergLilly Raises UK Obesity Shot Price as Trump Pressures Pharma (Bloomberg) -- Eli Lilly & Co. is raising the list price for its obesity shot in the UK by as much as 170%, as the pharma industry comes u